These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28442578)

  • 41. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis.
    Carr W; Bernstein J; Lieberman P; Meltzer E; Bachert C; Price D; Munzel U; Bousquet J
    J Allergy Clin Immunol; 2012 May; 129(5):1282-1289.e10. PubMed ID: 22418065
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Olfaction in patients with allergic rhinitis: an indicator of successful MP-AzeFlu therapy.
    Klimek L; Poletti SC; Sperl A; Spielhaupter M; Bardenhewer C; Mullol J; Hörmann K; Hummel T
    Int Forum Allergy Rhinol; 2017 Mar; 7(3):287-292. PubMed ID: 27888645
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis.
    Carr WW; Ratner P; Munzel U; Murray R; Price D; Canonica GW; Mullol J; Virchow JC; Lieberman P; Meltzer E; Bachert C
    Allergy Asthma Proc; 2012; 33(6):450-8. PubMed ID: 23127291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Comparative Bioavailability of Fluticasone and Azelastine Delivered as a Single Fixed Dose Combination (MP-AzeFlu) in Comparison to Two Different Formulations of Azelastine and Fluticasone Propionate Following Intranasal Administration in Healthy Chinese Volunteers.
    Qi W; Liu Y; Xue W; Li K; Gorski JC; Liu M; Yan T; Nguyen DT; Ramalingam RK
    J Asthma Allergy; 2023; 16():667-677. PubMed ID: 37409000
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis.
    Lieberman P; Kaliner MA; Wheeler WJ
    Curr Med Res Opin; 2005 Apr; 21(4):611-8. PubMed ID: 15899111
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel.
    Lipworth B; Newton J; Ram B; Small I; Schwarze J
    NPJ Prim Care Respir Med; 2017 Jan; 27(1):3. PubMed ID: 28115736
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis.
    Ridolo E; Montagni M; Melli V; Bonzano L; Incorvaia C; Canonica GW
    Ther Deliv; 2015; 6(6):653-9. PubMed ID: 25913181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial.
    Berger W; Sher E; Gawchik S; Fineman S
    Allergy Asthma Proc; 2018 Mar; 39(2):110-116. PubMed ID: 29490769
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MP29-02: a breakthrough for the treatment of allergic rhinitis.
    Bernstein JA
    Expert Opin Pharmacother; 2013 Oct; 14(15):2101-13. PubMed ID: 23977840
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis.
    Scadding G; Bousquet J; Bachert C; Fokkens WJ; Hellings PW; Prokopakis E; Pfaar O; Price D
    Rhinology; 2019 Feb; 57(1):49-56. PubMed ID: 30052697
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate.
    Derendorf H; Meltzer EO; Hermann R; Canonica GW
    Drugs Today (Barc); 2014 Jan; 50(1):15-31. PubMed ID: 24524103
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management.
    Bachert C; Bousquet J; Hellings P
    Clin Transl Allergy; 2018; 8():25. PubMed ID: 29983907
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis.
    Berger WE; Shah S; Lieberman P; Hadley J; Price D; Munzel U; Bhatia S
    J Allergy Clin Immunol Pract; 2014; 2(2):179-85. PubMed ID: 24607046
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment with azelastine hydrochloride and fluticasone propionate in a single delivery device of young children and adolescents with allergic rhinitis.
    Berger WE; Mustakov TB; Kralimarkova TZ; Christoff G; Popov TA
    Allergy Asthma Proc; 2020 Jul; 41(4):232-239. PubMed ID: 32605694
    [No Abstract]   [Full Text] [Related]  

  • 55. Influence of MP 29-02 on ciliary beat frequency in human epithelial cells in vitro.
    Häussler D; Sommer JU; Nastev A; Aderhold C; Wenzel A; Kramer B; Stuck BA; Birk R
    Eur Arch Otorhinolaryngol; 2018 Jun; 275(6):1483-1490. PubMed ID: 29675754
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis.
    Banov CH; Lieberman P;
    Ann Allergy Asthma Immunol; 2001 Jan; 86(1):28-35. PubMed ID: 11206234
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the drug monitoring programme of azelastine hydrochloride nasal spray in the treatment of allergic rhinitis in children under 13 years of age.
    Wober W; Diez Crespo CD; Bähre M
    Arzneimittelforschung; 1997 Jul; 47(7):841-4. PubMed ID: 9272242
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: a randomized, multicenter, double-blind, single-dose, crossover study.
    Meltzer EO; Stahlman JE; Leflein J; Meltzer S; Lim J; Dalal AA; Prillaman BA; Philpot EE
    Clin Ther; 2008 Feb; 30(2):271-9. PubMed ID: 18343265
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of MP-AzeFlu enhanced by activation of bitter taste receptor TAS2R.
    Ekstedt S; Kumlien Georén S; Cardell LO
    Allergy Asthma Clin Immunol; 2020; 16():45. PubMed ID: 32514276
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of MP-AzeFlu compared to monotherapy on COX-2, PGE
    Vicens-Artes S; Roca-Ferrer J; Tubita V; Fuentes M; Alobid I; Valero A; Kopietz F; Nguyen D; Mullol J
    Immun Inflamm Dis; 2023 Jan; 11(1):e709. PubMed ID: 36705401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.